Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive (HR+), HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Testing effectiveness (Phase 2)Ended earlyNCT02990845
What this trial is testing

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Premenopausal Breast Cancer
National Taiwan University Hospital 16
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Testing effectiveness (Phase 2)Looking for participantsNCT06974604
What this trial is testing

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Who this might be right for
Breast NeoplasmsLung Neoplasms
Brown University 60
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Not applicableStudy completedNCT05584644
What this trial is testing

Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Neoplasms+2 more
Pfizer 150
Testing effectiveness (Phase 2)Ended earlyNCT04227327
What this trial is testing

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Who this might be right for
Advanced Breast Cancer
University of Milano Bicocca 31
Testing effectiveness (Phase 2)Ended earlyNCT05966584
What this trial is testing

Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT03056755
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 383
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Very early researchStudy completedNCT02802748
What this trial is testing

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 60
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Early research (Phase 1)Looking for participantsNCT07137871
What this trial is testing

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Who this might be right for
Breast Cancer Metastatic
The University of Texas Health Science Center at San Antonio 35
Not applicableLooking for participantsNCT04968964
What this trial is testing

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 55
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Not applicableEnded earlyNCT03786107
What this trial is testing

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583
Next Page